InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024
May 6, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") announces that the evaluation of options for the future of the Company, including the reverse merger communicated in a press release on April 8, 2024 (the “Transaction”), is still ongoing. In a separate press release, the Board of Directors of InDex Pharmaceuticals convenes an Extraordinary General Meeting to be held on June 10, 2024.Following the discontinuation of the development of cobitolimod and the announcement that the Company will not continue the development of any of its other